NYSE$NEUE
NeueHealth Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported strong performance due to progress in reducing medical costs, accurate risk adjustment capture, and improving operational performance.
Bright Health Group reported a revenue of $1.6 billion, up 41.5% from Q2'21. The GAAP Net Loss was $251.3 million, and the Adjusted EBITDA Loss was $194.9 million. The Enterprise Medical Cost Ratio was 88.8%. The company reaffirmed its 2022 Consolidated Revenue, MCR, and Adjusted EBITDA guidance.
- Revenue of $1.6 billion, up 41.5% from Q2'21.
- GAAP Net Loss of $251.3 million.
- Adjusted EBITDA Loss of $194.9 million.
- Enterprise Medical Cost Ratio of 88.8%.
Headline financials
Revenue & EPS history
NeueHealth · Revenue · Quarterly
$1.58B
Forward guidance
Bright Health Group expects a total revenue of $6.8 billion to $7.1 billion with an expected enterprise Medical Cost Ratio between 90% and 94%. Bright HealthCare end-of-year membership is expected to be approximately 1,000,000, while NeueHealth Revenue is expected to be approximately $2.2 billion. Adjusted EBITDA for 2022 is expected to be a loss of between $500.0 million and $800.0 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2022
-2.0%
Avg return
Earnings day
-6.9%
Avg return
5 days after
-17.7%
Avg return
30 days after
45%
10 / 22 earnings
Positive
+46.5%
Q1 2023
Best reaction
-43.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.0% | -2.2% | -2.1% | |
| Q1 2025 | -2.2% | -0.4% | -1.5% | |
| Q4 2024 | +8.9% | +30.9% | +29.9% | |
| Q3 2024 | +2.2% | +2.5% | +7.8% | |
| Q2 2024 | -3.6% | +2.3% | -4.4% | |
| Q1 2024 | -4.0% | -3.7% | -14.3% | |
| Q4 2023 | +7.6% | -6.0% | -27.7% | |
| Q3 2023 | -1.5% | -10.2% | -15.5% | |
| Q2 2023 | -21.8% | -27.8% | -61.3% | |
| Q1 2023 | +46.5% | +7.2% | -14.1% | |
| Q4 2022 | -43.1% | -48.8% | -77.2% | |
| Q3 2022 | +4.3% | -3.7% | -15.3% | |
| Q2 2022 | -9.3% | +2.1% | -15.1% | |
| Q1 2022 | +35.7% | +26.0% | -0.6% | |
| Q4 2019 | -2.6% | -1.3% | -16.4% | |
| Q4 2021 | -29.5% | -42.9% | -35.6% | |
| Q3 2020 | +1.3% | -13.1% | -15.4% | |
| Q3 2021 | -35.1% | -34.4% | -40.5% | |
| Q2 2020 | +5.1% | — | — | |
| Q1 2021 | +5.1% | — | — | |
| Q4 2020 | +5.1% | — | — | |
| Q2 2021 | -13.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro